TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus.
Inhibition of RND-Type Efflux Pumps Confers the FtsZ-Directed Prodrug TXY436 with Activity against Gram-Negative Bacteria.
Pharmacokinetics and in Vivo Antistaphylococcal Efficacy of TXY541, a 1-Methylpiperidine-4-Carboxamide Prodrug of PC190723.
An FtsZ-Targeting Prodrug with Oral Antistaphylococcal Efficacy in Vivo.
Enterococcal and Streptococcal Resistance to PC190723 and Related Compounds: Molecular Insights from a FtsZ Mutational Analysis.
TXA497 as a Topical Antibacterial Agent: Comparative Antistaphylococcal, Skin Deposition, and Skin Permeation Studies with Mupirocin.
Antibacterial Activity of Quinoxalines, Quinazolines, and 1,5-Naphthyridines.
Substituted 1,6-Diphenylnaphthalenes as FtsZ-Targeting Antibacterial Agents.
Antimicrobial Activity of Various 4- and 5-Substituted 1-Phenylnaphthalenes.
Phenyl-Substituted 6,7-Dimethoxyisoquinoline Derivatives as FtsZ-Targeting Antibacterial Agents.
A Bactericidal Guanidinomethyl Biaryl That Alters the Dynamics of Bacterial FtsZ Polymerization.
Antibacterial Activity of Substituted 5-Methylbenzo[c]phenanthridinium Derivatives.
Antibacterial Activity of Substituted Dibenzo[a,g]quinolizin-7-ium Derivatives.